Breaking News, Financial News

Financial Report: Johnson & Johnson

Revenues up 9% in the quarter driven by new products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson   2Q Revenues: $19.5 billion (+9%) 2Q Earnings: $4.3 billion (+13%) YTD Revenues: $37.6 billion (+6%) YTD Earnings: $9.1 billion (+24%) Comments: Pharmaceutical sales were $8.5 billion, up 21%, with domestic sales up 37% and international sales up 7%. Growth was primarily driven by new products including OLYSIO/SOVRIAD (simeprevir), for chronic hepatitis C; XARELTO (rivaroxaban), an oral anticoagulant; ZYTIGA for the treatment of metastatic, castration-resistant prostat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters